EA202190360A1 - Комбинированная терапия - Google Patents

Комбинированная терапия

Info

Publication number
EA202190360A1
EA202190360A1 EA202190360A EA202190360A EA202190360A1 EA 202190360 A1 EA202190360 A1 EA 202190360A1 EA 202190360 A EA202190360 A EA 202190360A EA 202190360 A EA202190360 A EA 202190360A EA 202190360 A1 EA202190360 A1 EA 202190360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination therapy
inhibitor
effective amount
kinase
methods
Prior art date
Application number
EA202190360A
Other languages
English (en)
Inventor
Дэниел П. Голд
Original Assignee
Мей Фарма, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мей Фарма, Инк filed Critical Мей Фарма, Инк
Publication of EA202190360A1 publication Critical patent/EA202190360A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем документе предусмотрены способы лечения заболеваний, таких как рак, с применением комбинированной терапии. В соответствии с определенными вариантами осуществления способы предусматривают введение пациенту эффективного количества ингибитора фосфоинозитид-3-киназы (PI3K) и эффективного количества ингибитора циклин-зависимой киназы (CDK).
EA202190360A 2018-08-14 2019-08-13 Комбинированная терапия EA202190360A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718925P 2018-08-14 2018-08-14
PCT/US2019/046405 WO2020036995A1 (en) 2018-08-14 2019-08-13 Combination therapy

Publications (1)

Publication Number Publication Date
EA202190360A1 true EA202190360A1 (ru) 2021-07-15

Family

ID=69525833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190360A EA202190360A1 (ru) 2018-08-14 2019-08-13 Комбинированная терапия

Country Status (9)

Country Link
US (1) US20210161909A1 (ru)
JP (1) JP2021534114A (ru)
CN (1) CN112839651A (ru)
AU (1) AU2019322858A1 (ru)
EA (1) EA202190360A1 (ru)
IL (1) IL280729A (ru)
MX (1) MX2021001764A (ru)
TW (1) TW202021592A (ru)
WO (1) WO2020036995A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023167856A1 (en) * 2022-03-01 2023-09-07 Mei Pharma, Inc. Combination therapy of pi3k inhibitor and pd-1 inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2491140T3 (es) * 2006-06-21 2014-09-05 Piramal Enterprises Limited Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
SG193982A1 (en) * 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
JP7114478B2 (ja) * 2016-03-28 2022-08-08 プレサージュ バイオサイエンシズ，インコーポレイテッド 癌の治療のための配合剤
KR20190058550A (ko) * 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
MX2019013862A (es) * 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
BR112020002984A2 (pt) * 2017-08-14 2020-08-11 Mei Pharma, Inc. terapia combinada

Also Published As

Publication number Publication date
MX2021001764A (es) 2021-04-19
US20210161909A1 (en) 2021-06-03
IL280729A (en) 2021-03-25
WO2020036995A1 (en) 2020-02-20
TW202021592A (zh) 2020-06-16
CN112839651A (zh) 2021-05-25
JP2021534114A (ja) 2021-12-09
AU2019322858A1 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
EA202092154A1 (ru) Комбинированная терапия
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX2019003134A (es) Terapia de combinacion.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201792304A1 (ru) Комбинированная терапия для лечения рака
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
MX2020001727A (es) Terapia de combinacion.
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2019013862A (es) Terapia de combinacion.
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
PH12021551276A1 (en) Combination therapy for the treatment of cancer
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA202190360A1 (ru) Комбинированная терапия
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина